Bristol-Myers SquibbBMY

A U.S. appeals court has revived a $6.7 billion lawsuit involving Bristol Myers and former shareholders of Celgene, a company it acquired in 2019. The suit claims Bristol Myers intentionally slowed down the federal approval process for three drugs, including the cancer treatment Breyanzi, to avoid making multi-billion dollar payments that were triggered only if those drugs hit specific deadlines.

While the company has denied these claims, the revival of the case brings a massive potential bill back into play. For a company already spending heavily to replace revenue from older drugs losing their patent protection, a multi-billion dollar legal hit would be a significant setback to its cash reserves.

Source: Reuters

The U.S. Food and Drug Administration has approved a new combination therapy from Bristol Myers for patients with a rare blood cancer. This approval is specifically for cases where the cancer has relapsed or failed to respond to previous treatments.

This is a win for the company's growth strategy. Bristol Myers is currently racing to launch new medicines to replace the billions in sales it will lose as its older blockbuster drugs lose their patent protection. Every new approval for a specialized treatment helps build the "growth portfolio" the company needs to stabilize its long-term revenue.

Source: Reuters

Bristol Myers announced it will spend about $2.3 billion to construct a new manufacturing plant in Houston. This project is part of a larger $40 billion commitment the company has made to invest in its U.S. operations.

Building high-tech manufacturing sites is a necessary but expensive part of the company's shift toward newer, more complex therapies. While this is a large cash outlay, it ensures the company has the capacity to produce its next generation of drugs in-house as it tries to move past its reliance on older medicines.

Source: Reuters

Reports that Bristol Myers Squibb was in talks for a massive 400 billion dollar merger with AstraZeneca appear to have been premature. A senior source close to the matter says there are no discussions currently taking place between the two drugmakers.

This settles the speculation that drove the stock higher earlier in the week. While a merger of that size would have fundamentally changed the company, the denial means the focus returns to its current plan. The company is still working to replace revenue from its older drugs with a new group of younger treatments.

Source: Reuters

The company is partnering with Schrödinger to use an AI tool called Bunsen in its research labs. This software is designed to act as a digital co-scientist, helping researchers find and develop new drug candidates more efficiently. Finding new drugs is a slow and expensive process that often ends in failure. By using AI to better predict which molecules might work before they even reach a lab, the company hopes to lower its research costs and get successful treatments to the market faster.

Source: Business Wire